UK Home Office Contract

RNS Number:8219X
Cozart PLC
06 June 2007

                                   Cozart plc


      Cozart appointed into 4-year Framework Agreement with UK Home Office
              for Laboratory Oral Fluid Drug Confirmation Testing


               First year contract win worth approximately #700k


Abingdon, Oxfordshire, 6 June 2007 - Cozart plc ('Cozart' or the 'Company'), the
medical diagnostics company, announces a significant contract win with the UK
Home Office, for the laboratory confirmation testing of oral fluid samples for
the presence of drugs of abuse. The initial contract, for one year, is based on
a four year Framework Agreement between Cozart and the Home Office, established
following a OJEU competitive tendering process.

Cozart has been selected as the sole supplier to the Home Office for this first
annual contract. It is estimated that first year revenues will be approximately
#700k.

The confirmation testing of oral fluid samples will be performed at Cozart's
UKAS ISO 17025:2005 accredited laboratories in Abingdon, UK, where the Company
employs the sophisticated confirmation techniques of gas chromatography with
mass spectrometry (GC/MS), liquid chromatography with tandem mass spectrometry
(LC/MS/MS) and gas chromatography with tandem mass spectrometry (GC/MS/MS).
Cozart's laboratories will provide confirmation (if and when required) of the
presence or absence of the class A drugs cocaine and heroin following screening
in police custody suites across England & Wales as part of the Home Office Drug
Interventions Programme. The screening of arrestees in 173 police custody suites
will continue to use the Cozart(R) RapiScan on-site oral fluid drug screening
system which provides the on-site result from the oral fluid sample in just 3
minutes.

Cozart's analytical services laboratories allow the Company to offer a complete
portfolio of laboratory screening and confirmation services in support of its
leading edge on-site drug testing products such as the Cozart(R) RapiScan and
Cozart(R) DDS for the point-of-contact detection of drugs in oral fluid.

Dr. Chris Hand, Chief Executive of Cozart, said: "This new contract strengthens
Cozart's technology based position as the leading provider of oral fluid drug
testing products and services in Europe. This contract win, following a full
competitive tendering process, is further validation of our approach of offering
the customer a comprehensive portfolio of on-site drug testing products with
full laboratory support."



Enquiries:


Cozart plc:
Tel: 01235 861 483
Dr Chris Hand, Chief Executive
Chris Yates, Finance Director
www.cozartgroup.com


Financial Dynamics:
Tel:  020 7269 7242
Ben Atwell
Anna Keeble




Notes to Editors - Cozart plc

Cozart is a medical diagnostics company which develops, manufactures and sells
immunodiagnostic tests, predominantly those used for the detection of drugs of
abuse. Cozart's products include laboratory based testing kits for the detection
of drugs in a variety of biological samples and the Cozart(R) RapiScan and
Cozart DDS systems, portable devices used for the on-site testing of drugs of
abuse in saliva (oral fluid) samples. In July 2004 Cozart floated on London's
AIM (trading symbol: CZT).   Cozart has wholly owned subsidiaries in Spain
(Spinreact SA based near Barcelona); Sweden (HL Scandinavia and Medib
Scandinavian), Italy (Cozart Italia) and UK (Nemesis Scientific Limited).

Cozart supplies point of contact testing products, laboratory services and
forensic testing kits to the criminal justice (e.g. police forces, probation
services and prisons), medical (e.g. hospitals and drug dependency clinics) and
workplace markets (e.g. pre-employment, random and 'for cause' testing) both in
the UK and internationally.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCSSAFIISWSELM
Cozart (LSE:CZT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024